Why the study?
It was unknown whether low-normal LVEF is associated with adverse outcomes in HCM or adds incremental predictive value to the conventional HCM SCD-risk model.
Does low-normal or reduced LVEF increase the risk of adverse outcomes in patients with hypertrophic cardiomyopathy?
Population
1858 patients with HCM from two tertiary hospitals
Comparison
Low-normal LVEF (50%–60%) and reduced LVEF (<50%) vs preserved LVEF (≥60%)
Design
Retrospective cohort study
Follow-up
Median 4.09 years
Key result
Reduced LVEF (<50%) was an independent predictor of sudden cardiac death/equivalent events with an adjusted HR of 5.214 compared to preserved LVEF in patients with hypertrophic cardiomyopathy.
Authors
Loading...
May warrant closer SCD surveillance in HCM with reduced LVEF; extends risk models but remains hypothesis-generating.
Cohort (n=1,858)
Yes
Does low-normal or reduced LVEF increase the risk of adverse outcomes in patients with hypertrophic cardiomyopathy?
Effect estimate: HR 5.214 (95% CI 1.574 to 17.274)
p-value: p=0.007
In patients with hypertrophic cardiomyopathy, low-normal LVEF (50%-60%) is an independent predictor of heart failure hospitalization and cardiovascular death, while reduced LVEF (<50%) strongly predicts sudden cardiac death.
Choi et al. (2022) conducted a cohort in Hypertrophic Cardiomyopathy (n=1,858). Reduced LVEF (<50%) was an independent predictor of sudden cardiac death/equivalent events with an adjusted HR of 5.214 compared to preserved LVEF in patients with hypertrophic cardiomyopathy.